TG Therapeutics posts Q3 revenue beat, raises full‑year revenue guidance to about $1 billion
TG Therapeutics reported third‑quarter 2026 revenue of $259.9 million, topping forecasts by roughly $14 million, while GAAP earnings per share came in at $0.35, slightly below consensus. The company lifted its full‑year 2026 revenue target to approximately $1 billion, up from $950 million, and increased its BRIUMVI U.S. net product revenue outlook to $915‑$920 million. Management also highlighted a 61% year‑over‑year revenue jump and outlined a subcutaneous BRIUMVI launch slated for 2028, with a simplified IV initiation regimen expected mid‑2027.
Why it matters
The raised revenue guidance signals higher expected sales for the year, which could support a higher valuation for the stock. The upcoming product launches may further expand the company’s market opportunity.
Key facts
- 1GAAP EPS for Q3 2026 was $0.35, missing estimates by $0.01. seekingalpha.com
- 2Revenue for Q3 2026 was $259.9 million, beating expectations by $14.45 million. seekingalpha.com
- 3Full‑year 2026 revenue guidance was raised to $1 billion from $950 million. seekingalpha.com
- 4BRIUMVI U.S. net product revenue guidance was raised to $915 million‑$920 million from $890 million‑$905 million. seekingalpha.com
- 5Cash, cash equivalents and investment securities totaled $556.7 million at quarter‑end. tradingview.com
- 6BRIUMVI U.S. net product revenue in Q3 was $232.6 million, about 52% higher than the same quarter a year earlier. tradingview.com
Open questions
- Material 1 says EPS missed by $0.01, while material 4 says EPS missed by $0.02 on the same GAAP basis.
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.